2017 Q2 Form 10-Q Financial Statement
#000119312517169790 Filed on May 15, 2017
Income Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.070M | $1.170M | $2.440M |
| YoY Change | -18.32% | -52.05% | 43.53% |
| % of Gross Profit | |||
| Research & Development | $3.444M | $3.772M | $4.377M |
| YoY Change | -18.5% | -13.82% | 39.57% |
| % of Gross Profit | |||
| Depreciation & Amortization | $0.00 | $1.000K | $1.000K |
| YoY Change | 0.0% | -50.0% | |
| % of Gross Profit | |||
| Operating Expenses | $4.514M | $4.946M | $6.814M |
| YoY Change | -18.39% | -27.41% | 40.79% |
| Operating Profit | -$4.514M | -$4.946M | -$6.814M |
| YoY Change | -18.39% | -27.41% | 40.79% |
| Interest Expense | $10.00K | $10.00K | $10.00K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $6.000K | $9.000K | $14.00K |
| YoY Change | -50.0% | -35.71% | 0.0% |
| Pretax Income | -$4.510M | -$4.940M | -$6.800M |
| YoY Change | -18.3% | -27.35% | 40.79% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$4.508M | -$4.937M | -$6.800M |
| YoY Change | -18.32% | -27.4% | 40.9% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$130.0K | -$145.6K | -$235.9K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 34.67M shares | 34.06M shares | 28.83M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $9.130M | $13.64M | $22.36M |
| YoY Change | -49.28% | -39.0% | -23.82% |
| Cash & Equivalents | $9.127M | $13.64M | $22.36M |
| Short-Term Investments | |||
| Other Short-Term Assets | $200.0K | $350.0K | $430.0K |
| YoY Change | -16.67% | -18.6% | -29.51% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $9.329M | $14.00M | $22.78M |
| YoY Change | -48.86% | -38.56% | -23.96% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | |||
| YoY Change | |||
| Goodwill | |||
| YoY Change | |||
| Intangibles | $7.000K | ||
| YoY Change | -50.0% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $0.00 | $0.00 | $7.000K |
| YoY Change | -100.0% | -100.0% | -50.0% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $9.329M | $14.00M | $22.78M |
| Total Long-Term Assets | $0.00 | $0.00 | $7.000K |
| Total Assets | $9.329M | $14.00M | $22.79M |
| YoY Change | -48.87% | -38.58% | -23.97% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $399.0K | $1.346M | $1.311M |
| YoY Change | -57.19% | 2.67% | 42.19% |
| Accrued Expenses | $3.045M | $3.016M | $1.939M |
| YoY Change | 15.52% | 55.54% | 425.47% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $3.512M | $4.362M | $3.250M |
| YoY Change | -3.41% | 34.22% | 151.74% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $3.512M | $4.362M | $3.250M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $3.512M | $4.362M | $3.250M |
| YoY Change | -3.41% | 34.22% | 151.74% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$173.7M | -$168.9M | -$147.1M |
| YoY Change | 13.63% | 14.86% | 18.6% |
| Common Stock | $35.00K | $35.00K | $28.00K |
| YoY Change | 20.69% | 25.0% | 21.74% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $4.094M | $7.912M | $12.47M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $9.329M | $14.00M | $22.79M |
| YoY Change | -48.87% | -38.58% | -23.97% |
Cashflow Statement
| Concept | 2017 Q2 | 2017 Q1 | 2016 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.508M | -$4.937M | -$6.800M |
| YoY Change | -18.32% | -27.4% | 40.9% |
| Depreciation, Depletion And Amortization | $0.00 | $1.000K | $1.000K |
| YoY Change | 0.0% | -50.0% | |
| Cash From Operating Activities | -$5.010M | -$3.860M | -$3.490M |
| YoY Change | 8.68% | 10.6% | -19.03% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | ||
| YoY Change | |||
| Cash From Investing Activities | $0.00 | ||
| YoY Change | |||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $2.145M | ||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 480.0K | 2.150M | 0.000 |
| YoY Change | 84.62% | -100.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -5.010M | -3.860M | -3.490M |
| Cash From Investing Activities | 0.000 | ||
| Cash From Financing Activities | 480.0K | 2.150M | 0.000 |
| Net Change In Cash | -4.530M | -1.710M | -3.490M |
| YoY Change | 4.14% | -51.0% | -1686.36% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$5.010M | -$3.860M | -$3.490M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
34670684 | shares |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
208125 | shares |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22356000 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
34670684 | shares |
| CY2017Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
1234797 | shares |
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
34670684 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4656888 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.30 | |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-168910000 | |
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
4362000 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
13997000 | |
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
173000 | |
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1346000 | |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
7912000 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
35000 | |
| CY2017Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
169548000 | |
| CY2017Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
50000 | |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4362000 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3016000 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
13997000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13644000 | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
864000 | |
| CY2017Q1 | us-gaap |
Assets
Assets
|
13997000 | |
| CY2017Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
353000 | |
| CY2017Q1 | galt |
Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
|
20000000 | shares |
| CY2017Q1 | galt |
Undesignated Capital Stock Shares Outstanding
UndesignatedCapitalStockSharesOutstanding
|
20000000 | shares |
| CY2017Q1 | galt |
Undesignated Capital Stock Par Value
UndesignatedCapitalStockParValue
|
0.01 | |
| CY2017Q1 | galt |
Undesignated Capital Stock Value
UndesignatedCapitalStockValue
|
0 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25846000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
32912942 | shares |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
32912942 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4656888 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.30 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-163701000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
3780000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
15795000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
614000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
910000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10292000 | |
| CY2016Q4 | us-gaap |
Dividends Payable Current
DividendsPayableCurrent
|
68000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
33000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
166721000 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
14000 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3780000 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2802000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
26400000 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15362000 | |
| CY2016Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
15795000 | |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
432000 | |
| CY2016Q4 | galt |
Undesignated Capital Stock Shares Authorized
UndesignatedCapitalStockSharesAuthorized
|
20000000 | shares |
| CY2016Q4 | galt |
Undesignated Capital Stock Shares Outstanding
UndesignatedCapitalStockSharesOutstanding
|
14001000 | shares |
| CY2016Q4 | galt |
Undesignated Capital Stock Par Value
UndesignatedCapitalStockParValue
|
0.01 | |
| CY2016Q4 | galt |
Undesignated Capital Stock Value
UndesignatedCapitalStockValue
|
0 | |
| CY2016 | galt |
Accrued Research And Development Costs And Other
AccruedResearchAndDevelopmentCostsAndOther
|
2174000 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
21218186 | shares |
| CY2017Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2017Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | |
| CY2017Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2017Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001133416 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-3863000 | |
| CY2017Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> <b>1.    Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> Galectin Therapeutics Inc. (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease, skin diseases and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form <font style="WHITE-SPACE: nowrap">10-Q</font> reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March 31, 2017 and the results of its operations for the three months ended March 31, 2017 and 2016 and its cash flows for the three months ended March 31, 2017 and 2016. All adjustments made to the interim financial statements include all those of a normal and recurring nature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2016 are derived from the Company’s audited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through the date these financial statements are available to be issued. The results for interim periods are not necessarily indicative of results which may be expected for any other interim period or for the full year. The unaudited condensed consolidated financial statements of the Company should be read in conjunction with its Annual Report on Form <font style="WHITE-SPACE: nowrap">10-K</font> for the year ended December 31, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company has operated at a loss since its inception and has had no significant revenues. The Company anticipates that losses will continue for the foreseeable future. At March 31, 2017, the Company had $13.6 million of unrestricted cash and cash equivalents available to fund future operations. The Company believes that with the cash on hand at March 31, 2017, there is sufficient cash to fund currently planned operations through December 31, 2017. The Company’s ability to fund operations after its current cash resources are exhausted depends on its ability to obtain additional financing or achieve profitable operations, as to which no assurances can be given. Accordingly, based on the forecasts and estimates underlying the Company’s current operating plan, the financial statements do not currently include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"> The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name <font style="WHITE-SPACE: nowrap">“Pro-Pharmaceuticals,</font> Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011.</p> </div> | |
| CY2017Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2017Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-03-31 | |
| CY2017Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | dei |
Trading Symbol
TradingSymbol
|
GALT | |
| CY2017Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.000 | pure |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
0 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33928000 | shares |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.15 | |
| CY2017Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
GALECTIN THERAPEUTICS INC | |
| CY2017Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P10M24D | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.00 | pure |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4946000 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4937000 | |
| CY2017Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
9000 | |
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
9000 | |
| CY2017Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5209000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-79000 | |
| CY2017Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1000 | |
| CY2017Q1 | us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
14000 | |
| CY2017Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
272000 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2145000 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
330000 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1174000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2145000 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3772000 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1718000 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
650000 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
4946000 | |
| CY2017Q1 | galt |
Accrued Research And Development Costs And Other
AccruedResearchAndDevelopmentCostsAndOther
|
2793000 | |
| CY2017Q1 | galt |
Supplemental Dividends On Convertible Preferred Stock
SupplementalDividendsOnConvertiblePreferredStock
|
339000 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15032827 | shares |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-3490000 | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.017 | pure |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
1.05 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28827000 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
277500 | shares |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
69375 | shares |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.24 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.94 | pure |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6814000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6800000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
14000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
14000 | |
| CY2016Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7010000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-129000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
153000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1223000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2437000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
|
57000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4377000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-3490000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1957000 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
6814000 | |
| CY2016Q1 | galt |
Supplemental Dividends On Convertible Preferred Stock
SupplementalDividendsOnConvertiblePreferredStock
|
220000 |
